AstraZeneca expects to get US emergency authorization for its COVID-19 vaccine in April, the firm’s president told lawmakers on Tuesday.
As soon as it gets the Food and Drug Administration’s (FDA) greenlight, AstraZeneca will have 30 million doses of the 62 percent effective shot ready to ship to the US, said president of the biopharmaceuticals arm of the company, Dr Ruud Dobber on Tuesday.
He told members of the House of Representatives’ Committee on Energy and Commerce that the company could deliver ‘up to 50 million’ doses by the end of April.
The Trump Administration inked a deal with AstraZeneca for 300 million doses of its Oxford University-designed vaccine.
It has already been authorized by more than 50 countries and the World Health Organization, but mistrust brewed between the pharma giant and US regulators, who placed its large late-stage US trial on a nearly seven-week hold.
Meanwhile, AstraZeneca’s easily stored, $4 shot has helped countries like the UK speed ahead of the US in the vaccination race, and data from Scotland this week suggested the shot reduces hospital admissions by 94 percent…